Processing

Please wait...

Settings

Settings

Goto Application

1. EP0473725 - COMPOSITION AND METHOD TO DETECT SENSITIVITY TO ALPHA INTERFERON THERAPY

Office European Patent Office
Application Number 90909944
Application Date 25.05.1990
Publication Number 0473725
Publication Date 11.03.1992
Publication Kind A4
IPC
G01N 33/567
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
566using specific carrier or receptor proteins as ligand binding reagent
567utilising isolate of tissue or organ as binding agent
G01N 33/53
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
G01N 33/577
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
577involving monoclonal antibodies
C07K 14/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
C07K 15/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
15Peptides or proteins having an unknown or only partially known sequence of aminoacids; Derivatives thereof
12characterised by partial structures
14Glycoproteins
CPC
C07K 16/3038
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
3038Kidney, bladder
C07K 14/705
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
C07K 16/30
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
G01N 33/57438
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
574for cancer
57407Specifically defined cancers
57438of liver, pancreas or kidney
G01N 33/57492
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
574for cancer
57484involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
57492involving compounds localized on the membrane of tumor or cancer cells
G01N 2800/52
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2800Detection or diagnosis of diseases
52Predicting or monitoring the response to treatment; Prognosis
Applicants SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH
Inventors ALBINO, ANTHONY, P.
NANUS, DAVID, M.
BANDER, NEIL, H.
PFEFFER, LAWRENCE, M.
Priority Data 07357075 25.05.1989 US
Title
(DE) ZUSAMMENSETZUNG UND VERFAHREN ZUR BESTIMMUNG DER EMPFINDLICHKEIT GEGEN ALPHA-INTERFERON-THERAPIE.
(EN) COMPOSITION AND METHOD TO DETECT SENSITIVITY TO ALPHA INTERFERON THERAPY
(FR) COMPOSITION ET PROCEDES DE DETECTION DE SENSIBILITE A UNE THERAPIE A L'INTERFERON ALPHA.
Abstract
(EN)
This invention provides the hybridoma designated F 33 (ATCC No. HB 10155) and the monoclonal antibody produced by it. This invention also provides a method of detecting the sensitivity of a malignant cell or tissue to alpha interferon therapy which comprises contacting a sample of the malignant cell or tissue with a monoclonal antibody which recognizes an epitope of gp 160 cell surface antigen under conditions such that an antibody-antigen complex is formed between the monoclonal antibody and the gp 160 cell surface antigen, if the antigen is present in the sample; and detecting any complex so formed, the absence of complex indicating that the malignant cell or tissue is sensitive to alpha interferon therapy.

(FR)
L'invention concerne l'hybridome appelé F 33 (ATCC No. HB 10155) ainsi que l'anticorps monoclonal produit par celui-ci. L'invention concerne également un procédé de détection de la sensibilité d'une cellule ou d'un tissu malin à une thérapie à l'interféron alpha, consistant à mettre en contact un échantillon de ladite cellule ou dudit tissu malin, avec un anticorps monoclonal reconnaissant un épitope de l'antigène de surface cellulaire de la gp 160, dans des conditions telles qu'un complexe anticorps-antigène est formé entre ledit anticorps monoclonal et ledit antigène de surface cellulaire de la gp 160, si l'antigène est présent dans ledit échantillon; et à détecter tout complexe ainsi formé, l'absence de complexe indiquant que la cellule ou le tissu malin est sensible à une thérapie à l'interféron alpha.

Also published as
NO19914587